EUCTR2005-003894-26-PT进行中（未招募）不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible for this study if they meet the following criteria:
- •1.)AF documented as follows:
- •a.There is ECG documented AF on the day of screening or randomization
- •b.The patient has had a symptomatic episode of paroxysmal or persistent AF documented by 12 lead ECG within six months prior to randomization
- •c.There is documentation of symptomatic or asymptomatic paroxysmal or persistent AF on two separate occasions, at least one day apart, one of which is within six months prior to randomization. In this case, AF may be documented by 12 lead ECG, rhythm strip, pacemaker/ICD electrogram, or Holter ECG. The duration of AF should be at least 30 seconds. Electrograms (not marker channels or mode switch episodes) from pacemakers and defibrillators can be used to document only one episode of paroxysmal or persistent AF
- •2.)In addition to documented AF, patients must have one of the following additional risk factors for stroke:
- •a.History of previous stroke, transient ischemic attack, or systemic embolism
- •b.Left ventricular ejection fraction <40% documented by echocardiogram, radionuclide or contrast angiogram
- •c.Symptomatic heart failure, documented to be NYHA Class 2 or greater
- •d.Age = 75 years
- •e.Age = 65 years and one of the following additional risk factors:
- •i)diabetes mellitus on treatment
- •ii)documented coronary artery disease (any of: prior MI, positive stress exercise test, positive nuclear perfusion study, prior CABG surgery or PCI, angiogram showing =75% stenosis in a major coronary artery
- •iii)hypertension requiring medical treatment
- •3.)Age =18 years at entry
- •4.)Written, informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.)History of heart valve disorders (i.e., prosthetic valve or hemodynamically relevant valve disease)
- •2.)Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
- •3.)Conditions associated with an increased risk of bleeding:
- •4.)Contraindication to warfarin treatment
- •5.)Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
- •6.)Plan to perform a pulmonary vein ablation or surgery for cure of the AF
- •7.)Severe renal impairment (estimated creatinine clearance =30 mL/min)
- •8.)Active infective endocarditis
- •9.)Active liver disease, including but not limited to
- •a.Persistent ALT, AST, Alk. Phos. >2 x ULN
- •b.Known active hepatitis C (as evidenced by positive HCV RNA by sensitive PCR based assay, such as Roche Monitor or Bayer TMA assay)
- •c.Active hepatitis B (HBs antigen +, anti HBc IgM+)
- •d.Active hepatitis A
- •10.)Women who are pregnant or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study (NOTE: A negative pregnancy test must be obtained for any woman of childbearing potential prior to entry into the study)
- •11.)Anaemia (haemoglobin <100g/L) or thrombocytopenia (platelet count <100 x 10^9/L)
- •12.)Patients who have developed transaminase elevations upon exposure to ximelagatran.
- •13.)Patients who have received an investigational drug in the past 30 days
- •14.)Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).
研究者
相似试验
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYEUCTR2005-003894-26-ATBoehringer Ingelheim Austria GmbH15,000
进行中（未招募）
1 期
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYEUCTR2005-003894-26-GBBoehringer Ingelheim Ltd.18,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-DKBoehringer Ingelheim Pharma GmbH & Co KG18,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial FibrillationEUCTR2005-003894-26-DEBoehringer Ingelheim Pharma GmbH & Co. KG18,000
进行中（未招募）
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYEUCTR2005-003894-26-SEBoehringer Ingelheim AB15,000